 Connection
John Carroll to Secondary Prevention
This is a "connection" page, showing publications John Carroll has written about Secondary Prevention.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.532 |
|
|
|
-
Wiktor DM, Carroll JD. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke. Circ Cardiovasc Interv. 2018 03; 11(3):e004152.
Score: 0.550
-
Carroll JD, Saver JL. Patent foramen ovale and cryptogenic stroke. N Engl J Med. 2013 07 04; 369(1):91-2.
Score: 0.398
-
Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013 Mar 21; 368(12):1092-100.
Score: 0.390
-
Orjuela KD, Leppert MH, Carroll JD. Navigating the Gray: The Complex Story of PFO Closure Utilization. Circ Cardiovasc Qual Outcomes. 2024 01; 17(1):e010581.
Score: 0.206
-
Mess? SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, Carroll JD, Ishida K, Sangha N, Kasner SE. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020 05 19; 94(20):876-885.
Score: 0.160
-
Carroll AM, Carroll JD. Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials. Curr Cardiol Rep. 2019 04 22; 21(6):48.
Score: 0.149
-
Horlick E, Kavinsky CJ, Amin Z, Boudoulas KD, Carroll JD, Hijazi ZM, Leifer D, Lutsep HL, Rhodes JF, Tobis JM. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Catheter Cardiovasc Interv. 2019 04 01; 93(5):859-874.
Score: 0.148
-
Leppert MH, Poisson SN, Carroll JD, Thaler DE, Kim CH, Orjuela KD, Ho PM, Burke JF, Campbell JD. Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention. Stroke. 2018 06; 49(6):1443-1450.
Score: 0.139
-
Tirschwell DL, Turner M, Thaler D, Choulerton J, Marks D, Carroll J, MacDonald L, Smalling RW, Koullick M, Gu NY, Saver JL. Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention. J Med Econ. 2018 Jul; 21(7):656-665.
Score: 0.139
-
Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 09 14; 377(11):1022-1032.
Score: 0.133
-
Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, Derumeaux G, Furlan AJ, Herrmann HC, J?ni P, Kim JS, Koethe B, Lee PH, Lefebvre B, Mattle HP, Meier B, Reisman M, Smalling RW, Soendergaard L, Song JK, Mas JL, Thaler DE. Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke. JAMA. 2021 12 14; 326(22):2277-2286.
Score: 0.045
-
Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, Smalling RW, J?ni P, Mattle HP, Meier B, Thaler DE. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke. 2020 10; 51(10):3119-3123.
Score: 0.041
-
Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, Thourani VH, Carroll JD, Kirtane AJ, Bavaria JE, Cohen DJ, Kiefer TL, Gaca JG, Kapadia SR, Peterson ED, Vemulapalli S. Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. JAMA. 2018 12 04; 320(21):2231-2241.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|